Literature DB >> 20546119

Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy.

A Gatt1, A Riddell, V Calvaruso, E G Tuddenham, M Makris, A K Burroughs.   

Abstract

BACKGROUND: Prothrombin time (PT) and the international normalized ratio (INR) are still routinely measured in patients with liver cirrhosis to 'assess' their bleeding risk despite the lack of correlation with the two. Thrombin generation (TG) assays are global assays of coagulation that are showing promise in assessing bleeding and thrombosis risks. AIM: To study the relationship between the INR and TG profiles in cirrhosis-induced coagulopathy.
METHODS: Seventy-three patients with cirrhosis were studied. All TG parameters were compared with those from a normal control group. Contact activation was prevented using corn trypsin inhibitor. TG was also assayed in the presence of Protac(®). The endogenous thrombin potential (ETP) ratio was derived by dividing the ETP with Protac® by the ETP without Protac®.
RESULTS: The INR (mean 1.7) did not correlate with the ETP and the velocity of TG (P > 0.05). There was no difference between the lag time and ETP of the two groups (P > 0.05). The velocity of TG was increased in cirrhosis (67.95 ± 34.8 vs. 45.05 ± 25.9 nM min⁻¹ ; P = 0.016) especially in patients with INRs between 1.21 and 2.0. Both the ETP with Protac(®) and the ETP ratio were increased in cirrhosis (mean 1074 ± 461.4 vs. 818 ± 357.9 nM min, P = 0.004 and 0.80 ± 0.21 vs. 0.44 ± 0.15, P ≤ 0.0001, respectively).
CONCLUSION: Despite a raised INR, TG parameters are consistent with a hypercoagulable profile in cirrhosis-related coagulopathy. This confirms that the PT or INR should not be used to assess bleeding risk in these patients, and other parameters, such as TG, need to be explored as clinical markers of coagulopathy.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546119     DOI: 10.1111/j.1538-7836.2010.03937.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  37 in total

1.  Fibrinogen measurement in liver disease: validation of the functional fibrinogen thromboelastography assay and a novel mathematical predictive model.

Authors:  Kirsty Rizzo; Kevin Vella; Daniel Zammit; Peter Gatt; Charlie Grima; Monique Borg Inguanez; Jurgen Gerada; Pierre Ellul; Mario Vassallo; Neville Azzopardi; James Pocock; Alex Gatt
Journal:  Blood Transfus       Date:  2018-11-09       Impact factor: 3.443

Review 2.  Changing Concepts of Cirrhotic Coagulopathy.

Authors:  Armando Tripodi; Massimo Primignani; Pier M Mannucci; Stephen H Caldwell
Journal:  Am J Gastroenterol       Date:  2016-11-01       Impact factor: 10.864

3.  Role of anticoagulant therapy in liver disease.

Authors:  Elisabeth P C Plompen; Jeoffrey N L Schouten; Harry L A Janssen
Journal:  Hepatol Int       Date:  2013-03-26       Impact factor: 6.047

Review 4.  Venous thromboembolism in cirrhosis: a review of the literature.

Authors:  Michelle Buresi; Russell Hull; Carla S Coffin
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

Review 5.  Venous thromboembolism in cirrhosis.

Authors:  Zhineng J Yang; Karen A Costa; Enrico M Novelli; Roy E Smith
Journal:  Clin Appl Thromb Hemost       Date:  2012-10-17       Impact factor: 2.389

6.  Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury.

Authors:  Pierre-Emmanuel Rautou; Kohei Tatsumi; Silvio Antoniak; A Phillip Owens; Erica Sparkenbaugh; Lori A Holle; Alisa S Wolberg; Anna K Kopec; Rafal Pawlinski; James P Luyendyk; Nigel Mackman
Journal:  J Hepatol       Date:  2015-08-29       Impact factor: 25.083

Review 7.  Transfusion and coagulation management in liver transplantation.

Authors:  Ben Clevenger; Susan V Mallett
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 8.  Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review.

Authors:  Ashish Aggarwal; Kanika Puri; Suthat Liangpunsakul
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 9.  The hemostatic and thrombotic complications of liver disease.

Authors:  Hannah Stowe McMurry; Janice Jou; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2021-07-29       Impact factor: 2.997

10.  Thrombin Generation in Chronic Liver Diseases-A Pilot Study.

Authors:  Liliana Vecerzan; Ariela Olteanu; Ionela Maniu; Adrian Boicean; Călin Remus Cipăian; Horaţiu Dura; Sorin Radu Fleacă; Romeo Gabriel Mihăilă
Journal:  Healthcare (Basel)       Date:  2021-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.